• 목록
• 답변
• 작성
• 게시판 리스트 옵션
  • 수정
  • 삭제

S in sera of certain patients with systemic lupus erythematosus. J Exp Med 1987, 165:750-762.28. Senecal JL, Rauch J, Grodzicky T, Raynauld JP, Uthman I, Nava A, Guimond M, Raymond Y: Strong association of autoantibodies to human nuclear lamin B1 with lupus anticoagulant antibodies in systemic lupus erythematosus. Arthritis Rheum 1999, 42:1347-1353. 29. McKeon FD, Tuffanelli DL, Fukuyama K, Kirschner MW: Autoimmune response directed against conserved determinants of nuclear envelope proteins in a patient with linear scleroderma. Proc Natl Acad Sci USA 1983, 80:4374-4378. 30. Siapka S, Patrinou-Georgoula M, Vlachoyiannopoulos PG, Guialis A: Multiple specificities of autoantibodies against hnRNP A/B proteins in systemic rheumatic diseases and hnRNP L as an associated novel autoantigen. Autoimmunity 2007, 40:223-233. 31. Th ault S, Gilbert D, Hubert M, Drouot L, Machour N, Lange C, Charlionet R, Tron F: Orderly pattern of development of the autoantibody response in (New Zealand White ?BXSB)F1 lupus mice: characterization of target antigens and antigen spreading by two-dimensional gel electrophoresis and mass spectrometry. J Immunol 2002, 169:4046-4053. 32. Olahova M, Taylor SR, Khazaipoul S, Wang J, Morgan BA, Matsumoto K, Blackwell TK, Veal EA: A redox-sensitive peroxiredoxin that is important for longevity has tissue- and stress-specific roles in stress resistance. Proc Natl Acad Sci USA 2008, 105:19839-19844. 33. Choi MH, Lee IK, Kim GW, Kim BU, Han YH, Yu DY, Park HS, Kim KY, Lee JS, Choi C, Bae YS, Lee BI, Rhee SG, Kang SW: Regulation of PDGF signalling and vascular remodelling by peroxiredoxin II. Nature 2005, 435:347-353. 34. Karasawa R, Kurokawa MS, Yudoh K, Masuko K, Ozaki S, Kato T: Peroxiredoxin 2 is a novel autoantigen for anti-endothelial cell antibodies in systemic vasculitis. Clin Exp Immunol 2010, 161:459-470. 35. Lee MY, San Martin A, Mehta RRx-001 PK, Dikalova AE, Garrido AM, Datla SR, Lyons E, Krause KH, Banfi B, Lambeth JD, Lass ue B, Griendling KK: Mechanisms of vascular smooth muscle NADPH oxidase 1 (Nox1) contribution to injury-induced neointimal formation. Arterioscler Thromb Vasc Biol 2009, 29:480-487. 36. San Mart A, Lee MY, Williams HC, Mizuno K, Lass ue B, Griendling KK: Dual regulation of cofilin activity by LIM kinase and Slingshot-1L phosphatase controls platelet-derived growth factor-induced migration of human aortic smooth muscle cells. Circ Res 2008, 102:432-438. 37. Ooka S, Nakano H, Matsuda T, Okamoto K, Suematsu N, Kurokawa MS, Ohtani-Kaneko R, Masuko K, Ozaki S, Kato T: Proteomic surveillance of autoantigens in patients with Beh t's disease by a proteomic approach. PubMed ID:https://www.ncbi.nlm.nih.gov/pubmed/6833145 Microbiol Immunol 2010, 54:354-361. 38. Obeid M, Tesniere A, Ghiringhelli F, Fimia GM, Apetoh L, Perfettini JL, Castedo M, Mignot G, Panaretakis T, Casares N, M ivier D, Larochette N, van Endert P, Ciccosanti F, Piacentini M, Zitvogel L, Kroemer G: Calreticulin exposure dictates the immunogenicity of cancer cell death. Nat Med 2007, 13:54-61. 39. Seddiki N, Nato F, Lafaye P, Amoura Z, Piette JC, Mazie JC: Calreticulin, a potential cell surface receptor involved in cell penetration of anti-DNA antibodies. J Immunol 2001, 166:6423-6429. 40. Tuckova L, Karska K, Walters JR, Michalak M, Rossmann P, Krupickova S, Verdu EF, Saalman R, Hanson LA, Tlaskalova-Hogenova H: Anti-gliadin antibodies in patients with celiac disease cross-react with enterocytes and human calreticulin. Clin Immunol Immunopathol 1997, 85:289-296. 41. van den Berg RH, Siegert CE, Fab.